Comparative analysis of 0.1% cyclosporin A cationic emulsion and 0.05% cyclosporin A emulsion in murine dry eye cases with different severities

Jin,Rujun; Li,Ying; Li,Lan; Kim,Jonghwa; Yoon,Hyeon Jeong; Yoon,Kyung Chul

doi:10.3892/etm.2021.10797

Comparative analysis of 0.1% cyclosporin A cationic emulsion and 0.05% cyclosporin A emulsion in murine dry eye cases with different severities

Authors:
- Rujun Jin
- Ying Li
- Lan Li
- Jonghwa Kim
- Hyeon Jeong Yoon
- Kyung Chul Yoon
View Affiliations

Affiliations: Department of Ophthalmology, Chonnam National University Medical School and Hospital, Donggu, Gwangju 61469, Republic of Korea
Published online on: September 27, 2021 https://doi.org/10.3892/etm.2021.10797
Article Number: 1363
Copyright: © Jin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dry eye (DE), especially severe DE (SDE), can cause ocular surface defects and reduce the patient's quality of life. Several clinical studies have shown that 0.1% cyclosporin A cationic emulsion (CsA CE) could decrease corneal damage. However, no experimental study has reported the effect of 0.1% CsA CE on SDE. The present study aimed to compare the efficacy of 0.1% CsA CE with that of 0.05% CsA emulsion for ocular surface damage and inflammation in the cases of murine DE with different severities. Following exposure to desiccating stress and subcutaneous injection of scopolamine for 5 days, C57BL/6 female mice were divided into SDE and non‑SDE (NSDE) groups based on corneal fluorescein staining scores (CFSs). Mice from both groups were topically treated with 0.05% CsA emulsion or 0.1% CsA CE for 10 days. The results demonstrated that 0.1% CsA CE‑treated mice in the SDE and NSDE groups exhibited significant improvements in all the clinical and experimental parameters. Furthermore, the CFS of 0.1% CsA CE‑treated mice in the SDE group was lower compared with that of the 0.05% CsA‑treated mice. In addition, in the SDE group, 0.1% CsA CE‑treated mice had significantly lower levels of nuclear factor‑κB activation, inflammatory infiltrations and apoptosis on the ocular surface, and they also exhibited higher conjunctival goblet cell density compared with the 0.05% CsA‑treated mice. In summary, these findings indicated that 0.1% CsA CE was more effective than topical 0.05% CsA emulsion at improving corneal epithelial injury and decreasing the levels of inflammatory cytokines and T cells in mice with SDE.

View Figures

View References

1	Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, Gupta PK, Karpecki P, Lazreg S, Pult H, et al: TFOS DEWS II Diagnostic methodology report (2017). Ocul Surf. 15:539–574. 2017.PubMed/NCBI View Article : Google Scholar
2	Li Y, Cui L, Lee HS, Kang YS, Choi W and Yoon KC: Comparison of 0.3% hypotonic and isotonic sodium hyaluronate eye drops in the treatment of experimental dry eye. Curr Eye Res. 42:1108–1114. 2017.PubMed/NCBI View Article : Google Scholar
3	Yoon KC, De Paiva CS, Qi H, Chen Z, Farley WJ, Li DQ and Pflugfelder SC: Expression of Th-1 chemokines and chemokine receptors on the ocular surface of C57BL/6 mice: Effects of desiccating stress. Invest Ophthalmol Vis Sci. 48:2561–2569. 2007.PubMed/NCBI View Article : Google Scholar
4	Pflugfelder SC: Integrating restasis into the management of dry eye. Int Ophthalmol Clin. 46:101–103. 2006.PubMed/NCBI View Article : Google Scholar
5	Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, Na KS, Schaumberg D, Uchino M, Vehof J, et al: TFOS DEWS II Epidemiology report (2017). Ocul Surf. 15:334–365. 2017.PubMed/NCBI View Article : Google Scholar
6	Baudouin C, Creuzot-Garcher C, Hoang-Xuan T, Rigeade MC, Brouquet Y, Bassols A, Guillemin I, Benmedjahed K and Arnould B: Severe impairment of health-related quality of life in patients suffering from ocular surface diseases. J Fr Ophtalmol. 31:369–378. 2008.PubMed/NCBI View Article : Google Scholar
7	Perry HD and Donnenfeld ED: Topical 0.05% cyclosporin in the treatment of dry eye. Expert Opin Pharmacother. 5:2099–2107. 2004.PubMed/NCBI View Article : Google Scholar
8	Schultz C: Safety and efficacy of cyclosporine in the treatment of chronic dry eye. Ophthalmol Eye Dis. 6:37–42. 2014.PubMed/NCBI View Article : Google Scholar
9	Deveney T and Asbell PA: Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye. Clin Ophthalmol. 12:569–576. 2018.PubMed/NCBI View Article : Google Scholar
10	Kim HS, Kim TI, Kim JH, Yoon KC, Hyon JY, Shin KU and Choi CY: Evaluation of clinical efficacy and safety of a novel cyclosporin A nanoemulsion in the treatment of dry eye syndrome. J Ocul Pharmacol Ther. 33:530–538. 2017.PubMed/NCBI View Article : Google Scholar
11	Wirta DL, Torkildsen GL, Moreira HR, Lonsdale JD, Ciolino JB, Jentsch G, Beckert M, Ousler GW, Steven P and Krösser S: A clinical phase II study to assess efficacy, safety, and tolerability of waterfree cyclosporine formulation for treatment of dry eye disease. Ophthalmology. 126:792–800. 2019.PubMed/NCBI View Article : Google Scholar
12	Leonardi A, Van Setten G, Amrane M, Ismail D, Garrigue JS, Figueiredo FC and Baudouin C: Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: A multicenter randomized trial. Eur J Ophthalmol. 26:287–296. 2016.PubMed/NCBI View Article : Google Scholar
13	Eroglu YI: A comparative review of Haute Autorité de Santé and National Institute for Health and Care Excellence health technology assessments of Ikervis^® to treat severe keratitis in adult patients with dry eye disease which has not improved despite treatment with tear substitutes. J Mark Access Health Policy. 5(1336043)2017.PubMed/NCBI View Article : Google Scholar
14	Baudouin C, Figueiredo FC, Messmer EM, Ismail D, Amrane M, Garrigue JS, Bonini S, Leonardi A and Baudouin C: A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. Eur J Ophthalmol. 27:520–530. 2017.PubMed/NCBI View Article : Google Scholar
15	de Oliveira RC and Wilson SE: Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease. Clin Ophthalmol. 13:1115–1122. 2019.PubMed/NCBI View Article : Google Scholar
16	Yoon KC, De Paiva CS, Qi H, Chen Z, Farley WJ, Li DQ, Stern ME and Pflugfelder SC: Desiccating environmental stress exacerbates autoimmune lacrimal keratoconjunctivitis in non-obese diabetic mice. J Autoimmun. 30:212–221. 2008.PubMed/NCBI View Article : Google Scholar
17	Yoon KC, Ahn KY, Choi W, Li Z, Choi JS, Lee SH and Park SH: Tear production and ocular surface changes in experimental dry eye after elimination of desiccating stress. Invest Ophthalmol Vis Sci. 52:7267–7273. 2011.PubMed/NCBI View Article : Google Scholar
18	Villareal AL, Farley W and Pflugfelder SC: Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Eye Contact Lens. 32:272–276. 2006.PubMed/NCBI View Article : Google Scholar
19	Pauly A, Brignole-Baudouin F, Labbé A, Liang H, Warnet JM and Baudouin C: New tools for the evaluation of toxic ocular surface changes in the rat. Invest Ophthalmol Vis Sci. 48:5473–5483. 2007.PubMed/NCBI View Article : Google Scholar
20	Li Y, Jin R, Li L, Yoon HJ, Choi JH, Park JH, Liu Z, Li W, Li Z and Yoon KC: Expression and role of nucleotide-binding oligomerization domain 2 (NOD2) in the ocular surface of murine dry eye. Invest Ophthalmol Vis Sci. 60:2641–2649. 2019.PubMed/NCBI View Article : Google Scholar
21	Yoon KC, Park CS, You IC, Choi HJ, Lee KH, Im SK, Park HY and Pflugfelder SC: Expression of CXCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome. Invest Ophthalmol Vis Sci. 51:643–650. 2010.PubMed/NCBI View Article : Google Scholar
22	The definition and classification of dry eye disease. Report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 5:75–92. 2007.PubMed/NCBI View Article : Google Scholar
23	Baudouin C, Aragona P, Messmer EM, Tomlinson A, Calonge M, Boboridis KG, Akova YA, Geerling G, Labetoulle M and Rolando M: Role of hyperosmolarity in the pathogenesis and management of dry eye disease: Proceedings of the OCEAN group meeting. Ocul Surf. 11:246–258. 2013.PubMed/NCBI View Article : Google Scholar
24	Ambroziak AM, Szaflik J, Szaflik JP, Ambroziak M, Witkiewicz J and Skopiński P: Immunomodulation on the ocular surface: A review. Cent Eur J Immunol. 41:195–208. 2016.PubMed/NCBI View Article : Google Scholar
25	Lallemand F, Daull P, Benita S, Buggage R and Garrigue JS: Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Deliv. 2012(604204)2012.PubMed/NCBI View Article : Google Scholar
26	Rabinovich YI, Vakarelski IU, Brown SC, Singh PK and Moudgil BM: Mechanical and thermodynamic properties of surfactant aggregates at the solid-liquid interface. J Colloid Interface Sci. 270:29–36. 2004.PubMed/NCBI View Article : Google Scholar
27	Royle L, Matthews E, Corfield A, Berry M, Rudd PM, Dwek RA and Carrington SD: Glycan structures of ocular surface mucins in man, rabbit and dog display species differences. . 25:763–773. 2008.PubMed/NCBI View Article : Google Scholar
28	Daull P, Guenin S, Hamon de Almeida V and Garrigue JS: Anti-inflammatory activity of CKC-containing cationic emulsion eye drop vehicles. Mol Vis. 24:459–470. 2018.PubMed/NCBI
29	Hwang SB, Park JH, Kang SS, Kang DH, Lee JH, Oh SJ, Lee JY, Kim JY and Tchah H: Protective effects of cyclosporine A emulsion versus cyclosporine A cationic emulsion against desiccation stress in human corneal epithelial cells. Cornea. 39:508–513. 2020.PubMed/NCBI View Article : Google Scholar
30	Jurisic V: Multiomic analysis of cytokines in immuno-oncology. Expert Rev Proteomics. 17:663–674. 2020.PubMed/NCBI View Article : Google Scholar
31	Jurisic V, Terzic T, Colic S and Jurisic M: The concentration of TNF-alpha correlate with number of inflammatory cells and degree of vascularization in radicular cysts. Oral Dis. 14:600–605. 2008.PubMed/NCBI View Article : Google Scholar
32	Yang S, Wang J, Brand DD and Zheng SG: Role of TNF-TNF Receptor 2 signal in regulatory T cells and its therapeutic implications. Front Immunol. 9(784)2018.PubMed/NCBI View Article : Google Scholar
33	Pegoretti V, Baron W, Laman JD and Eisel UL: Selective modulation of TNF-TNFRs signaling: Insights for multiple sclerosis treatment. Front Immunol. 9(925)2018.PubMed/NCBI View Article : Google Scholar